Cite
Li L, Li J, Khanna M, et al. Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties. ACS Med Chem Lett. 2010;1(5):229-233doi: 10.1021/ml100031a.
Li, L., Li, J., Khanna, M., Jo, I., Baird, J. P., & Meroueh, S. O. (2010). Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties. ACS medicinal chemistry letters, 1(5), 229-233. https://doi.org/10.1021/ml100031a
Li, Liwei, et al. "Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties." ACS medicinal chemistry letters vol. 1,5 (2010): 229-233. doi: https://doi.org/10.1021/ml100031a
Li L, Li J, Khanna M, Jo I, Baird JP, Meroueh SO. Docking Small Molecules to Predicted Off-Targets of the Cancer Drug Erlotinib Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable In vitro Pharmacokinetic Properties. ACS Med Chem Lett. 2010 Aug 12;1(5):229-233. doi: 10.1021/ml100031a. PMID: 20824148; PMCID: PMC2931832.
Copy
Download .nbib